Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD: Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE Study

Alexander Häge; Kenneth K.C. Man; Sarah K. Inglis; Jan Buitelaar; Sara Carucci; Marina Danckaerts; Ralf W. Dittmann; Bruno Falissard; Peter Garas; Chris Hollis; Kerstin Konrad; Hanna Kovshoff; Elizabeth Liddle; Suzanne McCarthy; Antje Neubert; Peter Nagy; Eric Rosenthal; Edmund J.S. Sonuga-Barke; Alessandro Zuddas; Ian C.K. Wong; David Coghill; Tobias Banaschewski

doi:10.1177/10870547241232337

Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD: Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE Study

Alexander Häge, Kenneth K.C. Man, Sarah K. Inglis, Jan Buitelaar, Sara Carucci, Marina Danckaerts, Ralf W. Dittmann, Bruno Falissard, Peter Garas, Chris Hollis, Kerstin Konrad, Hanna Kovshoff, Elizabeth Liddle, Suzanne McCarthy, Antje Neubert, Peter Nagy, Eric Rosenthal, Edmund J.S. Sonuga-Barke, Alessandro Zuddas, Ian C.K. WongDavid Coghill, Tobias Banaschewski^*

^*Corresponding author for this work

Aston Pharmacy School

Research output: Contribution to journal › Article › peer-review

5 Citations (SciVal)

Abstract

Objective: Short-term RCTs have demonstrated that MPH-treatment significantly reduces ADHD-symptoms, but is also associated with adverse events, including sleep problems. However, data on long-term effects of MPH on sleep remain limited. Methods: We performed a 2-year naturalistic prospective pharmacovigilance multicentre study. Participants were recruited into three groups: ADHD patients intending to start MPH-treatment (MPH-group), those not intending to use ADHD-medication (no-MPH-group), and a non-ADHD control-group. Sleep problems were assessed with the Children’s-Sleep-Habits-Questionnaire (CSHQ). Results: 1,410 participants were enrolled. Baseline mean CSHQ-total-sleep-scores could be considered clinically significant for the MPH-group and the no-MPH-group, but not for controls. The only group to show a significant increase in any aspect of sleep from baseline to 24-months was the control-group. Comparing the MPH- to the no-MPH-group no differences in total-sleep-score changes were found. Conclusion: Our findings support that sleep-problems are common in ADHD, but don’t suggest significant negative long-term effects of MPH on sleep.

Original language	English
Pages (from-to)	699-707
Number of pages	9
Journal	Journal of Attention Disorders
Volume	28
Issue number	5
Early online date	22 Feb 2024
DOIs	https://doi.org/10.1177/10870547241232337
Publication status	Published - Mar 2024

Funding

This project has received funding from the EU Seventh Framework Programme for research, technological development and demonstration under grant agreement number 260576. The authors wish to thank the children and adolescents who took part in the study, and their families. MP.

Funders	Funder number
Seventh Framework Programme	260576

Keywords

ADHD
long-term safety
methylphenidate
pharmacovigilance
sleep problems

Access to Document

10.1177/10870547241232337

https://eprints.soton.ac.uk/487847/Licence: Other

Cite this

Häge, A., Man, K. K. C., Inglis, S. K., Buitelaar, J., Carucci, S., Danckaerts, M., Dittmann, R. W., Falissard, B., Garas, P., Hollis, C., Konrad, K., Kovshoff, H., Liddle, E., McCarthy, S., Neubert, A., Nagy, P., Rosenthal, E., Sonuga-Barke, E. J. S., Zuddas, A., ... Banaschewski, T. (2024). Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD: Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE Study. Journal of Attention Disorders, 28(5), 699-707. https://doi.org/10.1177/10870547241232337

@article{e3785fc9d63545ec8b989a19785b9e39,

title = "Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD: Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE Study",

abstract = "Objective: Short-term RCTs have demonstrated that MPH-treatment significantly reduces ADHD-symptoms, but is also associated with adverse events, including sleep problems. However, data on long-term effects of MPH on sleep remain limited. Methods: We performed a 2-year naturalistic prospective pharmacovigilance multicentre study. Participants were recruited into three groups: ADHD patients intending to start MPH-treatment (MPH-group), those not intending to use ADHD-medication (no-MPH-group), and a non-ADHD control-group. Sleep problems were assessed with the Children{\textquoteright}s-Sleep-Habits-Questionnaire (CSHQ). Results: 1,410 participants were enrolled. Baseline mean CSHQ-total-sleep-scores could be considered clinically significant for the MPH-group and the no-MPH-group, but not for controls. The only group to show a significant increase in any aspect of sleep from baseline to 24-months was the control-group. Comparing the MPH- to the no-MPH-group no differences in total-sleep-score changes were found. Conclusion: Our findings support that sleep-problems are common in ADHD, but don{\textquoteright}t suggest significant negative long-term effects of MPH on sleep.",

keywords = "ADHD, long-term safety, methylphenidate, pharmacovigilance, sleep problems",

author = "Alexander H{\"a}ge and Man, {Kenneth K.C.} and Inglis, {Sarah K.} and Jan Buitelaar and Sara Carucci and Marina Danckaerts and Dittmann, {Ralf W.} and Bruno Falissard and Peter Garas and Chris Hollis and Kerstin Konrad and Hanna Kovshoff and Elizabeth Liddle and Suzanne McCarthy and Antje Neubert and Peter Nagy and Eric Rosenthal and Sonuga-Barke, {Edmund J.S.} and Alessandro Zuddas and Wong, {Ian C.K.} and David Coghill and Tobias Banaschewski",

year = "2024",

month = mar,

doi = "10.1177/10870547241232337",

language = "English",

volume = "28",

pages = "699--707",

journal = "Journal of Attention Disorders",

issn = "1087-0547",

publisher = "SAGE",

number = "5",

}

Häge, A, Man, KKC, Inglis, SK, Buitelaar, J, Carucci, S, Danckaerts, M, Dittmann, RW, Falissard, B, Garas, P, Hollis, C, Konrad, K, Kovshoff, H, Liddle, E, McCarthy, S, Neubert, A, Nagy, P, Rosenthal, E, Sonuga-Barke, EJS, Zuddas, A, Wong, ICK, Coghill, D & Banaschewski, T 2024, 'Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD: Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE Study', Journal of Attention Disorders, vol. 28, no. 5, pp. 699-707. https://doi.org/10.1177/10870547241232337

TY - JOUR

T1 - Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD

T2 - Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE Study

AU - Häge, Alexander

AU - Man, Kenneth K.C.

AU - Inglis, Sarah K.

AU - Buitelaar, Jan

AU - Carucci, Sara

AU - Danckaerts, Marina

AU - Dittmann, Ralf W.

AU - Falissard, Bruno

AU - Garas, Peter

AU - Hollis, Chris

AU - Konrad, Kerstin

AU - Kovshoff, Hanna

AU - Liddle, Elizabeth

AU - McCarthy, Suzanne

AU - Neubert, Antje

AU - Nagy, Peter

AU - Rosenthal, Eric

AU - Sonuga-Barke, Edmund J.S.

AU - Zuddas, Alessandro

AU - Wong, Ian C.K.

AU - Coghill, David

AU - Banaschewski, Tobias

PY - 2024/3

Y1 - 2024/3

N2 - Objective: Short-term RCTs have demonstrated that MPH-treatment significantly reduces ADHD-symptoms, but is also associated with adverse events, including sleep problems. However, data on long-term effects of MPH on sleep remain limited. Methods: We performed a 2-year naturalistic prospective pharmacovigilance multicentre study. Participants were recruited into three groups: ADHD patients intending to start MPH-treatment (MPH-group), those not intending to use ADHD-medication (no-MPH-group), and a non-ADHD control-group. Sleep problems were assessed with the Children’s-Sleep-Habits-Questionnaire (CSHQ). Results: 1,410 participants were enrolled. Baseline mean CSHQ-total-sleep-scores could be considered clinically significant for the MPH-group and the no-MPH-group, but not for controls. The only group to show a significant increase in any aspect of sleep from baseline to 24-months was the control-group. Comparing the MPH- to the no-MPH-group no differences in total-sleep-score changes were found. Conclusion: Our findings support that sleep-problems are common in ADHD, but don’t suggest significant negative long-term effects of MPH on sleep.

AB - Objective: Short-term RCTs have demonstrated that MPH-treatment significantly reduces ADHD-symptoms, but is also associated with adverse events, including sleep problems. However, data on long-term effects of MPH on sleep remain limited. Methods: We performed a 2-year naturalistic prospective pharmacovigilance multicentre study. Participants were recruited into three groups: ADHD patients intending to start MPH-treatment (MPH-group), those not intending to use ADHD-medication (no-MPH-group), and a non-ADHD control-group. Sleep problems were assessed with the Children’s-Sleep-Habits-Questionnaire (CSHQ). Results: 1,410 participants were enrolled. Baseline mean CSHQ-total-sleep-scores could be considered clinically significant for the MPH-group and the no-MPH-group, but not for controls. The only group to show a significant increase in any aspect of sleep from baseline to 24-months was the control-group. Comparing the MPH- to the no-MPH-group no differences in total-sleep-score changes were found. Conclusion: Our findings support that sleep-problems are common in ADHD, but don’t suggest significant negative long-term effects of MPH on sleep.

KW - ADHD

KW - long-term safety

KW - methylphenidate

KW - pharmacovigilance

KW - sleep problems

UR - https://journals.sagepub.com/doi/10.1177/10870547241232337

UR - http://www.scopus.com/inward/record.url?scp=85186392143&partnerID=8YFLogxK

U2 - 10.1177/10870547241232337

DO - 10.1177/10870547241232337

M3 - Article

C2 - 38389266

AN - SCOPUS:85186392143

SN - 1087-0547

VL - 28

SP - 699

EP - 707

JO - Journal of Attention Disorders

JF - Journal of Attention Disorders

IS - 5

ER -

Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD: Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE Study

Abstract

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this